Research Papers:

The genetic variants in the PTEN/PI3K/AKT pathway predict susceptibility and CE(A)F chemotherapy response to breast cancer and clinical outcomes

Xiang Li, Ruishan Zhang, Zhuangkai Liu, Shuang Li and Hong Xu _

PDF  |  HTML  |  Supplementary Files  |  How to cite

Oncotarget. 2017; 8:20252-20265. https://doi.org/10.18632/oncotarget.15690

Metrics: PDF 1194 views  |   HTML 1960 views  |   ?  


Xiang Li1, Ruishan Zhang1, Zhuangkai Liu1, Shuang Li1, Hong Xu1

1Department of Breast Cancer, Cancer Hospital of China Medical University, Liaoning Cancer Hospital & Insititute, Dadong District, Shenyang City, Liaoning Province, 110042, P.R.China

Correspondence to:

Hong Xu, email: [email protected]

Keywords: breast cancer, PTEN/PI3K/AKT pathway, genetic polymorphisms, susceptibility, prognosis

Received: August 24, 2016     Accepted: January 04, 2017     Published: February 25, 2017


The PI3K/PTEN/AKT pathway play a critical role in balancing cell growth and death. Epidemiologic studies suggested that mutations of the PI3K/PTEN/AKT pathway genes are associated with cancer risk, yet no data are available for PTEN rs701848, PIK3CA rs2699887, and AKT1 rs2494752 polymorphism and breast cancer(BC) risk. A case-control study was performed in 920 BC patients and 908 healthy controls using the TaqMan assay method. Overall, individuals with PTEN rs701848 TC, CC and TC/CC genotypes showed significant increased BC risk (P=0.043, P=0.002, P=0.008, respectively), and the C allele carriers had a 1.224-fold significantly increased risk of developing BC (P= 0.003). Moreover, a higher frequency of AKT rs2494752 AG genotype was observed among cases (P=0.045). Individuals harboring rs2494752 AG/AA genotype had a vital increased susceptibility to BC in the dominant model (P=0.039). More importantly, AKT1 rs2494752 GG genotype showed significantly rates of response to NCT chemotherapy (P=0.048). Furthermore, AKT1 rs2494752 AG genotype carriers showed significantly shorter DFS time, and GG genotype as the independent prognostic factor (DFS: adjusted HR=1.523, 95% CI=1.012-2.293, P=0.044; OS: adjusted HR=2.321, 95% CI=1.281-4.204, P=0.005). Moreover, MDR analysis consistently revealed that the combination of 3 selected SNPs and 7 known risk factors represented the best model to predicting BC prognosis. The luciferase assay showed that the G allele of rs2494752 significantly increased AKT1 promoter activity. These results suggest that PTEN rs701848 and AKT1 rs2494752 polymorphisms might be a candidate pharmacogenomic factor to assess the susceptibility of BC and response and prognosis prediction for interindividualized CE(A)F chemotherapy in BC patients.

Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 15690